{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:00:23Z","timestamp":1774965623964,"version":"3.50.1"},"reference-count":211,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1053\/j.jvca.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:08:22Z","timestamp":1754492902000},"page":"3506-3524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Cardiovascular Pharmacotherapy. V. Molecular Targets in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1053","volume":"39","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.08.006_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstrom","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.jvca.2025.08.006_bib0002","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0003","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.08.006_bib0004","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2025.08.006_bib0005","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.amjcard.2022.10.014","article-title":"Overview of current and emerging therapies for amyloid transthyretin cardiomyopathy","volume":"185","author":"Maurer","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"10.1053\/j.jvca.2025.08.006_bib0007","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.08.006_bib0008","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated with amyloidosis","volume":"165","author":"Ng","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0009","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0010","article-title":"Microvascular obstruction in cardiac amyloidosis","author":"Netti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0011","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","article-title":"Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome","volume":"80","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0013","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0014","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0015","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archinte.1988.00380030168027","article-title":"Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement","volume":"148","author":"Pellikka","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0016","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.107.186093","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology","volume":"116","author":"Cooper","year":"2007","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0017","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.jvca.2025.08.006_bib0018","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0019","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0020","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0021","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014evidence based and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0022","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0023","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and xxtracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0025","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ehjci\/jeac249","article-title":"Non-invasive diagnosis of transthyretin cardiac amyloidosis utilizing typical late gadolinium enhancement pattern on cardiac magnetic resonance and light chains","volume":"24","author":"Slivnick","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0026","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantificatio, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0027","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0022-2836(78)90368-6","article-title":"Structure of prealbumin: secondart, tertiary, and quaternary interactions determined by Fourier refinement at 1.8 A","volume":"121","author":"Blake","year":"1978","journal-title":"J Mol Biol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0028","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-291X(85)91956-4","article-title":"Localization of the human prealbumin gene to chromosome 18","volume":"129","author":"Wallace","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.jvca.2025.08.006_bib0029","doi-asserted-by":"crossref","first-page":"9969","DOI":"10.3390\/ijms25189969","article-title":"A snapshot of the most recent transthyretin stabilizers","volume":"25","author":"Marotta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2025.08.006_bib0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.7754382","article-title":"Structure of a complex of two plasma proteins: transthyretin and renitol-binding protein","volume":"268","author":"Monaco","year":"1995","journal-title":"Science"},{"key":"10.1053\/j.jvca.2025.08.006_bib0031","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/74082","article-title":"Rational design of potent transthyretin amyloid disease inhibitors","volume":"7","author":"Klabunde","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0032","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial deformation of transthyretin is sufficient for amyloid fibrin formation in vitro","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry"},{"key":"10.1053\/j.jvca.2025.08.006_bib0033","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60321-6","article-title":"Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid","volume":"50","author":"Kelly","year":"1997","journal-title":"Adv Protein Chem"},{"key":"10.1053\/j.jvca.2025.08.006_bib0034","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/82815","article-title":"Mechanisms of amyloidogenesis","volume":"7","author":"Kelly","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0035","doi-asserted-by":"crossref","first-page":"27207","DOI":"10.1074\/jbc.M101024200","article-title":"Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants","volume":"276","author":"Quintas","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2025.08.006_bib0036","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/jmbi.2002.5441","article-title":"Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled amyloid-like fibrils","volume":"317","author":"Cardoso","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0037","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0038","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1038\/s41467-022-33591-4","article-title":"Cyro-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis","volume":"13","author":"Steinebrei","year":"2022","journal-title":"Nat Commun"},{"key":"10.1053\/j.jvca.2025.08.006_bib0039","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1073\/pnas.91.12.5602","article-title":"Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure","volume":"91","author":"Papys","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2025.08.006_bib0040","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1053\/j.jvca.2025.08.006_bib0041","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0042","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jchf.2024.08.019","article-title":"Cardiovascular risk factors and genetic risk in transthyretin V142I carriers","volume":"13","author":"Shetty","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0044","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1212\/WNL.48.6.1667","article-title":"A trinucleotide deletion in the transthyretin gene (delta V122) in a kindred with familial amyloidotic polyneuropathy","volume":"48","author":"Uemichi","year":"1997","journal-title":"Neurology"},{"key":"10.1053\/j.jvca.2025.08.006_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"key":"10.1053\/j.jvca.2025.08.006_bib0046","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.5221","article-title":"Clinical phenotype and prognosis of asymptomatic patients with transthyretin cardiac amyloid infiltration","volume":"10","author":"Porcari","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0047","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modification of transthyretin modulated its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"key":"10.1053\/j.jvca.2025.08.006_bib0048","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangioni","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2025.08.006_bib0049","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis: a systematic review and meta-analsysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0051","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0052","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0053","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0054","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ehjci\/jead032","article-title":"Prevalence and significance of relative apical sparing in aortic stenosis: insights from an echo and cardiovascular magnetic resonance study of patients referred for surgical aortic valve replacement","volume":"24","author":"Abecasis","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0055","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2003.08.043","article-title":"Noninvasive diagnosis of biopsy-proven cardiac amyloidosis","volume":"43","author":"Rahman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0056","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0057","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0058","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0059","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0060","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0061","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.08.006_bib0062","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0063","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030271","article-title":"Amyloid transthyretin cardiomyopathy in elderly patients with aortic stenosis undergoing transcatheter aortic valve implantation","volume":"12","author":"Dobner","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.08.006_bib0064","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038279","article-title":"Coprevalence of amyloidosis and aortic stenosis: when to screen and who to treat?","volume":"14","author":"Sperry","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.08.006_bib0065","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.08.006_bib0066","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/jcm14103481","article-title":"Pharmacological management of transthyretin amyloid cardiomyopathy: where we are and where we are going","volume":"14","author":"De Michieli","year":"2025","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0067","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/phar.4639","article-title":"Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications","volume":"45","author":"Hellenbart","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.jvca.2025.08.006_bib0068","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0069","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0070","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0071","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.08.006_bib0072","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.08.006_bib0073","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.jvca.2025.08.006_bib0074","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1002\/ehf2.14975","article-title":"Effect of beta-blockade on mortality in patients with cardiac amyloidosis: a systematic review and meta-analysis","volume":"11","author":"Kwok","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0075","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"issue":"13 Pt 1","key":"10.1053\/j.jvca.2025.08.006_bib0076","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0077","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2025.08.006_bib0078","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1053\/j.jvca.2025.05.010","article-title":"Advances in cardiovascular pharmacotherapy. III. Sodium-glucose cotransporter type 2 inhibitors, part 1: efficacy in heart failure and myocardial infarction","volume":"39","author":"Pagel","year":"2025","journal-title":"J Cardiothoracic Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.08.006_bib0079","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analysis of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0080","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0081","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.amjmed.2025.02.010","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with amyloidosis with or without heart failure","volume":"138","author":"Augusto","year":"2025","journal-title":"Am J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0082","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14392","article-title":"Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis","volume":"55","author":"Karakasis","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.jvca.2025.08.006_bib0083","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.31.4.293","article-title":"A study of 159 Portuguese patient with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected","volume":"31","author":"Coelho","year":"1994","journal-title":"J Med Genet"},{"issue":"Suppl 1","key":"10.1053\/j.jvca.2025.08.006_bib0084","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/0960-8966(96)88826-2","article-title":"Compound heterozygotes of transthyretin Met30 and transthyreting Met119 are protected from the devastating effects of familial amyloid polyneuropathy","volume":"6","author":"Coelho","year":"1996","journal-title":"Neuromuscul Disord"},{"key":"10.1053\/j.jvca.2025.08.006_bib0085","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","article-title":"Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy","volume":"33","author":"Hornstrup","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0086","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstrom","year":"2003","journal-title":"Science"},{"issue":"Suppl 4","key":"10.1053\/j.jvca.2025.08.006_bib0087","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstrom","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2025.08.006_bib0088","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2025.08.006_bib0089","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2025.08.006_bib0090","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1021\/acschemneuro.0c00338","article-title":"Conventional molecular dynamics and metadynamics simulation studies of the binding and unbinding mechanism of TTR stabilizers AG10 and tafamidis","volume":"11","author":"Zhou","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1053\/j.jvca.2025.08.006_bib0091","article-title":"Molecular dynamics simulation study of AG10 and tafamidis binding to Val122Ile transthyretin variant","volume":"21","author":"Morris","year":"2020","journal-title":"Biochem Biophys Rep"},{"key":"10.1053\/j.jvca.2025.08.006_bib0092","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1053\/j.jvca.2025.08.006_bib0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1053\/j.jvca.2025.08.006_bib0094","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0095","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","article-title":"Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"10","author":"Maurer","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0096","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The bioequivalence of tafamidis 61-mg free acid capsules and tafamadis 4 x 20-mg capsules in healthy volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1053\/j.jvca.2025.08.006_bib0097","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.jvca.2025.08.006_bib0098","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalphy-derive stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2025.08.006_bib0099","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers","volume":"9","author":"Fox","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1053\/j.jvca.2025.08.006_bib0101","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/FJC.0000000000001726","article-title":"Differential binding affinities and kinetics of transthyretin stabilizers","volume":"86","author":"Ji","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0102","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0103","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients With ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0104","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0105","unstructured":"United States Food and Drug Administration. New drug therapy approvals 2019. https:\/\/web.archive.org\/web\/20200502164101\/https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/new-drug-therapy-approvals-2019. Published 2019. Accessed June 11, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0107","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000525883","article-title":"Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class III patients with transthyretin amyloid cardiomyopathy in the presence of death","volume":"147","author":"Li","year":"2022","journal-title":"Cardiology"},{"key":"10.1053\/j.jvca.2025.08.006_bib0108","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","article-title":"Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"8","author":"Sperry","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0109","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of tafamidis on renal function in patients With transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2022.100148","article-title":"Improvements in efficacy measures with tafamidis in the tafamidis in transthyretin cardiomyopathy clinical trial","volume":"1","author":"Hanna","year":"2022","journal-title":"JACC Adv"},{"key":"10.1053\/j.jvca.2025.08.006_bib0111","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analysis of ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0112","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0113","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliot","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0114","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ejhf.3190","article-title":"Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy","volume":"26","author":"Grogan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","article-title":"Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study","volume":"12","author":"Garcia-Pavia","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0116","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.amjcard.2023.08.036","article-title":"Outcomes of octogenarian patients treated wth tafamidis for transthyretin amyloid cardiomyopathy","volume":"214","author":"Sarkar","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0117","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/eurheartj\/ehae923","article-title":"Tafamidis in octogenarians with wild-type transthyretin amyloid cardiomyopathy: an international cohort study","volume":"46","author":"Debonnaire","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.08.006_bib0118","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3696","article-title":"Long-term efficacy of tafamidis in patients with tranthyretin amyloid cardiomyopathy by National Amyloidosis Center stage","author":"Damy","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0119","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0120","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/ejhf.3330","article-title":"Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction","volume":"26","author":"Drachman","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0121","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/ehf2.14815","article-title":"Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy","volume":"11","author":"Dobner","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0122","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-024-02576-2","article-title":"RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis","author":"Schwarting","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0123","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/biomedicines13051211","article-title":"Incidence and predictors of right ventricular reverse remodeling in paitents with tranthyretin amyloid cardiomyopathy treated with tafamidis","volume":"13","author":"Nita","year":"2025","journal-title":"Biomedicines"},{"key":"10.1053\/j.jvca.2025.08.006_bib0124","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10554-024-03293-7","article-title":"Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration","volume":"41","author":"Nagai","year":"2025","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034518","article-title":"Cardiac biomarker change at 1 year after tafamidis treatment and clinical outcome in patients with transthyretin amyloid cardiomyopathy","volume":"13","author":"Kuyama","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.08.006_bib0126","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0127","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid aardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0128","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissoociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci Res"},{"key":"10.1053\/j.jvca.2025.08.006_bib0130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0131","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcome in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0132","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf362","article-title":"Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis","author":"Nitsche","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.08.006_bib0133","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.08.006_bib0134","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1053\/j.jvca.2025.08.006_bib0135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0136","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-025-02159-z","article-title":"Acoramidis: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.08.006_bib0137","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0138","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jacc.2025.01.008","article-title":"Transthyretin amyloid cardiomyopathy: wherever protein stabilization leads, disease stabilization follows","volume":"85","author":"Grodin","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0139","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0140","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jacc.2025.04.014","article-title":"Serum transthyretin as a biomarker of treatment response in ATTR cardiomyopathy","volume":"85","author":"Regan","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0141","article-title":"Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy","volume":"17","author":"Ravi","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0142","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0143","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cardfail.2025.03.017","article-title":"Acoramidis for transthyretin amyloid cardiomyopathy: open-label extension study long-term follow-up","volume":"31","author":"Masri","year":"2025","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0144","unstructured":"Eidos Therapeutics. Acoramidis transthyretin amyloidosis prevention trial in the young (ACT-EARLY) study in asymptomatic carriers of a pathogenic TTR variant. https:\/\/clinicaltrials.gov\/study\/NCT06563895?cond=NCT06563895&rank=1. Published 2025. Accessed June 16, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0145","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0146","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1124\/molpharm.124.000895","article-title":"The growing class of novel RNAi therapeutics","volume":"106","author":"Traber","year":"2024","journal-title":"Mol Pharmacol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0147","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2025.08.006_bib0148","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1073\/pnas.1231012100","article-title":"Allele-specific silencing of dominant disease genes","volume":"100","author":"Miller","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2025.08.006_bib0149","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1053\/j.jvca.2025.08.006_bib0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1053\/j.jvca.2025.08.006_bib0151","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.08.006_bib0152","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/dmd.122.001107","article-title":"Clinical pharmacology of RNA interference-based therapeutics: a summary based on Food and Drug Administration-approved small interfering RNAs","volume":"51","author":"Jing","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.jvca.2025.08.006_bib0153","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisarin, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1053\/j.jvca.2025.08.006_bib0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.08.006_bib0156","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0157","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran preatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0158","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40265-023-01943-z","article-title":"Vutrisiran: a review in polyneuropathy of hereditary transthyretin-mediated amyloidosis","volume":"83","author":"Nie","year":"2023","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.08.006_bib0159","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0161","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2025.08.006_bib0162","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11886-024-02172-w","article-title":"Transthyretin cardiac amyloidosis: current and emerging therapies","volume":"27","author":"Patel","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"10.1053\/j.jvca.2025.08.006_bib0163","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jacc.2025.04.016","article-title":"The evolving therapeutic paradigm for cardiac amyloidosis","volume":"85","author":"Kadakia","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0164","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0165","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jacc.2025.03.477","article-title":"Impact of heart failure severity on vutrisiran efficacy in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0166","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jacc.2025.03.520","article-title":"Silence disease progression with early treatment of ATTR-CM","volume":"85","author":"Vaishnav","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0167","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jacc.2025.03.454","article-title":"Impact of vutrisiran on functional capacity and quality of life in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Sheikh","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0168","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2025.03.537","article-title":"Impact of vutrisiran on functional capacity and quality of life in ATTR cardiomyopathy","volume":"85","author":"Siddiqi","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0169","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B","volume":"85","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0170","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2025.04.015","article-title":"Transthyretin gene silencing in amyloid transthyretin cardiomyopathy: a novel treatment delivers new dilemmas","volume":"85","author":"Ambardekar","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0171","unstructured":"Ionis Pharmaceuticals. CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM). https:\/\/clinicaltrials.gov\/study\/NCT04136171?cond=CARDIO-TTRansform&rank=3. Published 2024. Accessed June 18, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0172","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0173","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0174","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrm.2017.132","article-title":"Mechanisms of clathrin-mediated endocytosis","volume":"19","author":"Kaksonen","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0175","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.celrep.2019.10.108","article-title":"RNase H1 and H2 are differentially regulated to process RNA-DNA hybrids","volume":"29","author":"Lockhart","year":"2019","journal-title":"Cell Rep"},{"key":"10.1053\/j.jvca.2025.08.006_bib0176","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.08.006_bib0177","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0178","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1111\/bcp.15468","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis","volume":"88","author":"Diep","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0179","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40120-022-00414-z","article-title":"Characteristics of patients with hereditary transthyretin-mediated amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRransform, an open-label phase 3 study of eplontersen","volume":"12","author":"Coelho","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1053\/j.jvca.2025.08.006_bib0180","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2025.08.006_bib0181","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1007\/s00415-024-12616-6","article-title":"Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform","volume":"271","author":"Conceicao","year":"2024","journal-title":"J Neurol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0182","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/13506129.2024.2427290","article-title":"Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRransform trial","volume":"32","author":"Wixner","year":"2025","journal-title":"Amyloid"},{"key":"10.1053\/j.jvca.2025.08.006_bib0183","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","article-title":"Eplontersen: first approval","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.08.006_bib0184","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin cardiomyopathy","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0185","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1161\/CIRCRESAHA.116.309727","article-title":"Gene editing with CRISPR\/Cas9 RNA-directed nuclease","volume":"120","author":"Doetschman","year":"2017","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2025.08.006_bib0186","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/jcp.30064","article-title":"CRISPR-Cas gene editing","volume":"236","author":"Zhang","year":"2021","journal-title":"J Cell Physiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0187","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cvr\/cvac048","article-title":"CRISPR and cardiovascular diseases","volume":"119","author":"Musunuru","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.08.006_bib0188","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0189","unstructured":"Intellia Therapeutics. MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM). https:\/\/clinicaltrials.gov\/study\/NCT06128629?cond=NCT06128629&rank=1. Published 2025. Accessed June 22, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0190","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl B","key":"10.1053\/j.jvca.2025.08.006_bib0191","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","article-title":"Monoclonal antibiodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis","volume":"25","author":"Emdin","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.08.006_bib0192","article-title":"Current and emerging treatment options for transthyretin amyloid cardiomyopathy","author":"Vergaro","year":"2025","journal-title":"Heart"},{"key":"10.1053\/j.jvca.2025.08.006_bib0193","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","article-title":"Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis","volume":"36","author":"Nuvolone","year":"2022","journal-title":"BioDrugs"},{"key":"10.1053\/j.jvca.2025.08.006_bib0194","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","article-title":"PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study","volume":"32","author":"Suhr","year":"2025","journal-title":"Amyloid"},{"key":"10.1053\/j.jvca.2025.08.006_bib0195","unstructured":"Nova Nordisk A\/S. A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have heart disease due to transthyretin (TTR) amyloidosis. https:\/\/clinicaltrials.gov\/study\/NCT05442047?cond=NCT05442047&rank=1. Published 2025. Accessed July 12, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0196","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.08.006_bib0197","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/cpt.3455","article-title":"Prediction of cardiac ATTR depletion by NI006 (ALXN2220) using mechanistic PK\/PD modeling","volume":"117","author":"Michalon","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.08.006_bib0198","article-title":"Antibody ALXN2220 (formerly NI006) for treatment of transthyretin cardiac amyloidosis","author":"Pillai","year":"2025","journal-title":"Cardiol Rev"},{"key":"10.1053\/j.jvca.2025.08.006_bib0199","unstructured":"Alexion Pharmaceuticals. Study of ALXN2220 versus placebo in adults with ATTR-CM (DepleTTR-CM). https:\/\/clinicaltrials.gov\/study\/NCT06183931?cond=NCT06183931&rank=1. Published 2025. Accessed July 12, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0200","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cardfail.2023.10.227","article-title":"The peptide fusion immunoglobulin, AT-02, exhibits highly potent pan-amyloid reactivity and immunomodulation","volume":"30","author":"Wall","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.08.006_bib0201","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11897-025-00701-4","article-title":"Etiological treatment of cardiac amyloidosis: standard of care and future directions","volume":"22","author":"Ferrari Chen","year":"2025","journal-title":"Curr Heart Fail Rep"},{"key":"10.1053\/j.jvca.2025.08.006_bib0202","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/HCO.0000000000001198","article-title":"New therapies to treat cardiac amyloidosis","volume":"40","author":"Nguyen","year":"2025","journal-title":"Curr Opin Cardiol"},{"key":"10.1053\/j.jvca.2025.08.006_bib0203","unstructured":"Attralus. Study of AT-02 in healthy volunteers and subjects with systemic amyloidosis (AT02-001). https:\/\/clinicaltrials.gov\/study\/NCT05521022?cond=NCT05521022&rank=1. Published 2025. Accessed July 12, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0204","unstructured":"Attralus. A study of AT-02 in subjects with systemic amyloidosis. https:\/\/clinicaltrials.gov\/study\/NCT05951049?cond=NCT05951049&rank=1. Published 2025. Accessed July 12, 2025."},{"key":"10.1053\/j.jvca.2025.08.006_bib0205","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/0259-1162.200235","article-title":"Sharma M: Amyloidosis and anesthesia","volume":"11","author":"Wani","year":"2017","journal-title":"Anesth Essays Res"},{"key":"10.1053\/j.jvca.2025.08.006_bib0206","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2023.111271","article-title":"Perioperative implications of amyloidosis and amyloid cardiomyopathy: a review for anesthesiologists","volume":"92","author":"Smith","year":"2024","journal-title":"J Clin Anesth"},{"key":"10.1053\/j.jvca.2025.08.006_bib0207","first-page":"1233","article-title":"Intraoperative death in cardiac amyloidosis with increased QT disperson in the electrocardiogram","volume":"80","author":"Tallgren","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2025.08.006_bib0208","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/BF03018462","article-title":"Laryngo-tracheo-bronchial stenosis in a patient with primary pulmonary amyloidosis: a case report and brief review","volume":"51","author":"Minogue","year":"2004","journal-title":"Can J Anaesth"},{"key":"10.1053\/j.jvca.2025.08.006_bib0209","article-title":"A case report on papillary muscle rupture following mitral valve replacement in the setting of previously undiagnosed amyloidosis","volume":"15","author":"Choudhury","year":"2021","journal-title":"A A Pract"},{"key":"10.1053\/j.jvca.2025.08.006_bib0210","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12630-021-02179-9","article-title":"Laryngeal amyloidosis","volume":"69","author":"Zhao","year":"2022","journal-title":"Can J Anaesth"},{"key":"10.1053\/j.jvca.2025.08.006_bib0211","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidosis and the heart: a clinical overview","volume":"10","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025006524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025006524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:13:10Z","timestamp":1774962790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077025006524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":211,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1053077025006524"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.08.006","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. V. Molecular Targets in Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}